Meeting
2019 ASCO Annual Meeting
A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.
Authors
Daniel J. DeAngelo
Dana-Farber Cancer Institute, Boston, MA
Daniel J. DeAngelo , Harry Paul Erba , Brian Andrew Jonas , Michael O'Dwyer , Paula Marlton , Gerwin A Huls , Jane Liesveld , Brenda W. Cooper , Bhavana Bhatnagar , Michael Armstrong , William Fogler , Mary Chen , John Magnani , Helen M. Thackray , Anjali S. Advani , Pamela Sue Becker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03616470
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS7066)
DOI
10.1200/JCO.2019.37.15_suppl.TPS7066
Abstract #
TPS7066
Poster Bd #
438b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML.
First Author: Richard M. Stone
Poster
2017 ASCO Annual Meeting
GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML.
First Author: Daniel J. DeAngelo
First Author: Matthew Raymond Smith
Poster
2014 ASCO Annual Meeting
First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
First Author: Tony Mok